IDEAYA Biosciences, Inc.IDYA

Ideaya Biosciences reported a quarterly net loss of $98.5 million for the three months ending March 2026, while its cash and cash equivalents declined to $157.5 million and operating cash burn reached $75.2 million. The company’s assets now total $1.03 billion against liabilities of $93.1 million, leaving equity at $937.3 million-enough to keep the lights on, but not enough to fund a full-blown commercial launch. Revenue clocked in at $6.6 million, less than 1% of the asset base, while R&D spend remained stubbornly high at $95.7 million. Diluted EPS was negative $1.11 on 88.7 million shares.

Ideaya describes itself as a precision medicine oncology company focused on targeted therapeutics for genetically defined cancers, with a pipeline anchored by darovasertib (a PKC inhibitor) and IDE892 (a PRMT5 inhibitor). The company’s most advanced asset, darovasertib, is being tested in combination with crizotinib for metastatic uveal melanoma, a rare and aggressive cancer where interim Phase 2 data have drawn regulatory interest but not yet reimbursement. IDE892 has just entered Phase 1/2 in MTAP-deleted pancreatic and lung cancers, staking the company’s claim in synthetic lethality and metabolic vulnerabilities. Ideaya also highlighted three abstract presentations at ESMO 2026 for darovasertib and IDE849, underscoring the science’s visibility in peer-reviewed fora even as commercial milestones remain distant.

Filing facts for the quarter ending 31 March 2026 show: revenue of $6.6 million; net loss attributable to parent of $98.5 million; operating loss of $108.5 million; total assets of $1.03 billion; liabilities of $93.1 million; stockholders’ equity of $937.3 million; cash and equivalents at $157.5 million; net cash used in operating activities of $75.2 million; capex of $967,000; R&D expense of $95.7 million; diluted weighted average shares outstanding of 88.7 million; and diluted loss per share of $1.11. The company’s 8-K and Form 4 filings in June-July 2026 document routine equity and insider transactions, including sales and dispositions by directors and 10b5-1 plans, alongside the 8-K announcing the $300 million common stock and pre-funded warrant offering on 25 June 2026.

For context on the company’s pipeline positioning, the SEC Company Facts API and EDGAR index confirm the latest disclosures for Ideaya Biosciences (CIK 0001676725), while the product brand visuals and newsroom materials reiterate the company’s oncology narrative and clinical ambitions. Ideaya’s investor page and media centre provide the public-facing chronology of abstract submissions, programme starts, and corporate updates, but none of these materials substitute for filed financials or regulatory approvals.

Ideaya’s clinical collaboration with F. Hoffmann-La Roche, announced on 3 June 2026, is framed as a validation of the darovasertib programme, though the collaboration’s financial terms remain confidential. The company’s June 2026 $300 million equity raise-structured as common stock and pre-funded warrants-was presented as growth capital, yet the cash burn rate implies runway measured in quarters rather than years. The company’s cash and equivalents stood at $157.5 million at quarter-end, a figure that will be watched closely as operating cash burn continues to outpace revenue by more than ten-to-one.

Ideaya’s ESMO 2026 abstract presentations are scheduled for September, giving the company a periodic research spotlight even as commercial execution remains pre-revenue. The company’s most advanced programme, darovasertib, has generated interim Phase 2 data but not yet registrational or payer-grade evidence. IDE892’s Phase 1/2 launch in MTAP-deleted cancers signals pipeline breadth, yet the absence of near-term catalysts beyond abstracts and study initiations keeps the equity story tethered to science rather than sales.

There is no public SEC filing evidence yet for revenue guidance, milestones, or regulatory approval timelines. The company has not filed a Form 8-K disclosing a pivotal trial design agreement or a Special Protocol Assessment with the FDA, nor has it published a revised cash runway estimate since the June 2026 financing. Until such filings appear, the market’s view of Ideaya will remain tethered to the balance sheet’s burn rate and the pipeline’s clinical cadence rather than to commercial metrics.